Kazia Therapeutics Limited
KZIA
$6.75
$0.172.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.52M | 1.52M | 1.52M | 758.90K | -- |
| Total Other Revenue | 128.70K | 121.40K | 113.90K | 57.20K | 600.00 |
| Total Revenue | 1.65M | 1.64M | 1.63M | 816.10K | 600.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.65M | 1.64M | 1.63M | 816.10K | 600.00 |
| SG&A Expenses | 9.31M | 9.13M | 8.91M | 7.38M | 5.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.73M | 20.56M | 20.33M | 16.57M | 12.91M |
| Operating Income | -19.08M | -18.92M | -18.69M | -15.75M | -12.91M |
| Income Before Tax | -18.91M | -18.38M | -17.76M | -14.14M | -10.59M |
| Income Tax Expenses | -178.70K | -178.70K | -177.70K | -178.30K | -180.10K |
| Earnings from Continuing Operations | -18.73 | -18.20 | -17.58 | -13.97 | -10.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.73M | -18.20M | -17.58M | -13.97M | -10.41M |
| EBIT | -19.08M | -18.92M | -18.69M | -15.75M | -12.91M |
| EBITDA | -17.85M | -17.69M | -17.47M | -14.52M | -11.66M |
| EPS Basic | -14.34K | -15.33K | -16.29K | -13.72K | -11.22K |
| Normalized Basic EPS | -18.65 | -19.67 | -20.63 | -18.96 | -17.42 |
| EPS Diluted | -14.34K | -15.33K | -16.29K | -13.72K | -11.22K |
| Normalized Diluted EPS | -18.65 | -19.67 | -20.63 | -18.96 | -17.42 |
| Average Basic Shares Outstanding | 2.85M | 2.48M | 2.11M | 1.98M | 1.85M |
| Average Diluted Shares Outstanding | 5.60K | 4.80K | 4.00K | 3.70K | 3.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |